Skip to content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
153 items
Transplanted microglia

Scientists develop new therapeutic model for potentially treating incurable eye diseases

Researchers have successfully transplanted human microglia into mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.

NEI Scientists publish recipe for making blood vessel cells from patient stem cells

Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries.
Schematic showing SREDs bind to G-protein coupled receptors to promote cell survival

UCI researchers discover new drugs with potential for treating world’s leading causes of blindness

In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

Extremely rare gene variants point to a potential cause of age-related macular degeneration

A study from the National Eye Institute (NEI) identified rare genetic variants that could point to one of the general mechanisms driving age-related macular degeneration (AMD), a common cause of vision loss in older adults.

Congressman Pete Sessions visits NIH

Texas Congressman Pete Sessions visited the NIH March 27 to meet with NEI Director Michael F. Chiang, M.D., and to tour NEI’s Section on Ocular and Stem Cell Translational Research, led by Kapil Bharti, Ph.D.

Night vision tests in age-related macular degeneration precisely localize disease mechanisms

Researchers at the University of Alabama at Birmingham discovered that night vision tests at a specific location in the retina will be suitable for assessing treatments and preventions for AMD.
blank

AI-based systems can help identify rapidly advancing age-related macular degeneration

Researchers supported by the NEI are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within two years.
Fundus photograph of age-related macular degeneration showing drusen.

Discovery suggests new way to prevent common causes of vision loss

UVA Health scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss.
Printed cells

NIH researchers use 3D bioprinting to create eye tissue

Scientists used patient stem cells and 3D bioprinting to produce eye tissue that will advance understanding of the mechanisms of blinding diseases.
retina blood vessels

One of two widely used AMD drugs outperforms other at weaning patients off treatment at one year, preliminary study shows

A pilot study of 106 patients with “wet” AMD revealed that nearly half of patients treated with Eylea could safely stop therapy after one year, compared to only 17% of patients treated with Avastin.

Want more news from NEI?

Connect with us through social media to stay up to date on vision research, eye health, and other topics!

NEI Press Office

We can connect media professionals with the latest vision research info. Get in touch!


Phone: 301-496-5248